The report "Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023", is expected to reach USD 700.8 million by 2027 from USD 377.2 million in 2018, at a CAGR of 8.4%.
Don’t miss out on business opportunities in Creatinine Measurement Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=206847385
“Single test panels to dominate the market in 2017”
Based on type, the global cellular health screening market is segmented into single test panels and multi-test panels. In 2017, the single test panels segment is expected to account for the largest share of the global cellular health screening market. These panels are used to get accurate information about a single biomarker and understand how it affects the health of an individual. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.
“Based on sample collection site, the at-home segment is projected to grow at the highest CAGR”
By sample collection site, the global cellular health screening market is segmented into at-home, in-office, and other sample collection sites. The at-home segment is expected to register the highest CAGR during the forecast period. The availability of diagnostic and therapeutic products that can be used by patients at home without assistance from healthcare professionals are expected to boost the demand for cellular health screening in this segment.
Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206847385
Key Players
F. Hoffmann-la Roche Ltd (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Thermo Fisher Scientific (US), Siemens Healthineers (Germany), Randox Laboratories (UK), Pointe Scientific (US), Sentinel Ch. Spa. (Italy), Diasys Diagnostic Systems GmbH (Germany), Dialab GmbH (Vienna), Diazyme Laboratories (US), Wako Pure Chemical Industries, Ltd. (Japan), Ortho Clinical Diagnostics (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)
F. Hoffmann-La Roche was the leading player in the creatinine measurement market in 2017. The dominant share of this company is attributed to its exhaustive product portfolio and strong global reach, especially in the emerging economies. For maintaining its market position, the company mainly focuses on investments toward R&D activities to fuel innovation. The company invested USD 10.18 billion (19.5% of total sales) on R&D activities in 2017. With its strong R&D capabilities and state-of-the-art asset quality, the company is also expected to grow during the forecast period.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=206847385